Back to Search
Start Over
Supplementary Figure 1 from KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF–Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)
- Publication Year :
- 2023
- Publisher :
- American Association for Cancer Research (AACR), 2023.
-
Abstract
- PDF file - 108KB, Predictive value of specific KRAS mutations in patients with BRAF-wild type resected stage III colon cancer treated with adjuvant FOLFOX chemotherapy with vs without cetuximab. Unadjusted hazard ratios (HR) for disease-free survival by KRAS mutation strata are shown for patients who were randomized during the period when KRAS-mutated and -wild type tumors were eligible. HR < 1 indicates benefit from cetuximab. No estimates produced due to insufficient sample size in one subgroup.
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....76b4763c88758e8f9e5682efd0996687